Silvester Krčméry, Rastislav Tahotný, Klára Soláriková
Utilizing of ACE inhibitors and AT1 blockers for receptors of angiotensin II (sartans) are reported in literature as prevention and deceleration of renal diseases progression. Differences in efficacy among a great number of ACEI molecules result from various pharmacokinetic features and occurrence of adverse effects. More clinical studies suggest combined therapy of ACEI and sartans as more efficient than monotherapy for proteinuria reduction and deceleration of renal insufficiency progression in patients with chronic renal diseases. In the light of present knowledge candidates for combined therapy are only some groups of patients with chronic nephropathy (patients with proteinuria > 1 g/24 hrs, with progressive loss of glomerular filtration within chronic glomerulonephritis activity, diabetic nephropathy, etc.). Potential risk of combination of ACEI and sartans is worsening of renal anemia and hyperkalemia.